There is a particular kind of email that lands in the inbox of a fast-growing online health brand at around the nine-month mark. It comes from a payment aggregator, it mentions “a review of your account activity”, and it gives the merchant somewhere between immediate effect and 14 days before settlements stop. Funds held for 90 to 180 days. Recurring subscriptions dead. Customer service queue on fire. Nothing about the business changed — the volume simply got big enough to be noticed.

For retailers and D2C operators watching the direct-to-consumer health boom from the outside, this is the part of the model that rarely makes the pitch deck. Telehealth consultations, compounded medications, research peptides, supplements with aggressive claims and the newer wave of prediction market platforms all share one structural feature: mainstream processors price and approve them on category risk, not on how well the individual business is run. Understanding why is useful well beyond those verticals, because the same underwriting logic governs subscription boxes, CBD, nutraceuticals and anything sold on a free-trial-to-rebill model.
The aggregator model is not built for regulated goods
Stripe, Square and PayPal are extraordinary products for ordinary commerce. They work because they onboard merchants in minutes under a master merchant agreement, then police risk afterwards by exception. That trade-off is deliberate: no underwriting friction up front, broad discretion to terminate later. When a merchant sells something that touches prescribing, licensing, or claims about the human body, “police by exception” means the account survives exactly until a compliance sweep, a card scheme enquiry, or a chargeback spike surfaces it.
Card network rules add a second layer. Visa and Mastercard maintain excessive-chargeback and high-integrity-risk programmes with monitoring thresholds, and acquirers that breach them pay fines and face remediation plans. A sponsor bank with a mixed portfolio therefore has a strong incentive to shed any merchant category that could pull its portfolio ratio upward. The payments trade press has covered this dynamic for years, and the Electronic Transactions Association’s analysis of how high-risk merchants get passed between providers in a hot potato game describes the pattern precisely: nobody wants to own the file, so the merchant is moved on rather than underwritten properly.
What actually triggers a decline or a shutdown
In practice, the reasons cluster into a short list, and most are fixable before you ever submit an application.
- Prohibited category by MCC. The merchant category code assigned at boarding is often wrong — a telehealth platform coded as general retail will eventually be reclassified, and reclassification is frequently accompanied by termination.
- Website claims that outrun the licence. Disease claims, dosage guidance, before-and-after imagery or “prescription included” language on a site with no visible prescriber oversight is the single fastest route to a declined application.
- Missing chain of custody. Underwriters want to see who dispenses, from where, and under whose authority. For compounded products that means a named 503A or 503B pharmacy partner; for anything controlled it means DEA registration, and absent that the category simply isn’t eligible.
- Negative-option billing. Free trials that roll into monthly charges are legal, but the disclosure, cancellation path and descriptor must be unambiguous or the chargeback ratio will do the talking.
- Thin or inconsistent paperwork. Processing statements that don’t match stated volume, a bank account in a different entity’s name, or a director who appears on the MATCH list will stop a file cold.
The underwriting file: assemble it before you need it
High-risk underwriting is a document exercise. The merchants who get approved quickly are not the lowest-risk ones; they are the ones whose file answers questions before they are asked. Expect to supply incorporation documents and beneficial ownership, three to six months of processing history or bank statements, a voided cheque or bank letter, government ID for signatories, and a clear description of the product and fulfilment chain.
For anything clinical, add the regulatory layer: state or national prescriber licences, the licensing map showing which jurisdictions you actually serve, pharmacy partner agreements, physician oversight protocols, telehealth consent language, and a privacy and security posture that stands up to scrutiny. If protected health information touches the payment flow — and in most prescribing platforms it does — you need a Business Associate Agreement with the processor and a design that keeps clinical data out of the transaction message. A gateway that passes a diagnosis code in a descriptor field is a HIPAA problem, not a payments one.
Choosing who to hand that file to matters as much as the file itself. The distinction between an aggregator, an ISO reselling someone else’s paper, and a provider with direct relationships across multiple acquiring banks determines whether a declined application is the end of the conversation or simply a redirect to a different bank. Our guide to avoiding bad decisions when choosing a payment provider sets out the questions worth asking before you sign, and they apply with extra force when your category is contentious.
Where a specialist account changes the economics
Specialist underwriting exists because the category needs it, not because it is a premium tier of the same product. A provider such as 2Accept underwrites verticals that mainstream aggregators restrict, connecting merchants to a network of acquiring banks and handling the underwriting, gateway integration and chargeback defence rather than leaving each to a different vendor. For a research-products brand, a purpose-built peptide merchant account means the MCC, descriptor and site review are correct from day one, the recurring refill schedule sits in a tokenised vault with Account Updater so expiring cards do not quietly kill the subscription base, and FSA/HSA card acceptance is available where the product qualifies. The same infrastructure supports HIPAA-compliant telemedicine and online prescribing platforms with BAA-backed setups, plus prediction market operators — with conditions attached, including DEA registration, named 503A or 503B pharmacy partners and documented physician oversight where the category requires them. Published figures put approval at 98% across 40+ acquiring banks, with a 48-hour average and go-live in 48 to 72 hours, and more than $2B processed yearly.
Recurring billing and chargeback defence as one system
Subscription revenue and dispute risk are the same problem viewed from two ends. Most “fraud” chargebacks on refill programmes are actually friendly fraud: the customer forgot, did not recognise the descriptor, or could not find the cancel button. The controls are unglamorous and effective.
- Make the billing descriptor match the brand the customer bought from, with a working phone number.
- Send a pre-debit reminder two to three days before each rebill, and keep the proof of send.
- Retain consent artefacts — timestamp, IP, checkout screenshot, terms version — as a dispute pack you can file in minutes.
- Use card-network alert services so a dispute can be refunded before it becomes a chargeback and counts against your ratio.
- Apply smart dunning and Account Updater to decline-driven churn, which is often larger than voluntary cancellation.
- Monitor your ratio weekly against the 0.9%% zone where monitoring programmes begin, not monthly in arrears.
Build the payments stack before the growth curve
The brands that survive a termination notice are the ones that already hold a second MID with a different acquirer, keep their compliance pack current, and treat payment infrastructure as a product decision rather than a plumbing afterthought. Nobody can promise guaranteed approval or a world without disputes. What is entirely achievable is being the best-documented merchant in the queue — and that is usually the difference between a 48-hour approval and a 180-day funds hold.
Terry Clark is the Publisher and Content Director of 365 Retail, with more than a decade of experience covering retail design, technology innovations, store openings and the wider retail industry. He also works closely with leading retailers, suppliers, agencies, events and industry awards across the UK.





















